Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Invested Capital (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Invested Capital for 5 consecutive years, with $210.6 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 17.98% to $210.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $210.6 million through Dec 2025, down 17.98% year-over-year, with the annual reading at $210.6 million for FY2025, 17.98% down from the prior year.
  • Invested Capital hit $210.6 million in Q4 2025 for ARS Pharmaceuticals, down from $243.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $369.0 million in Q1 2021 to a low of -$50.2 million in Q3 2022.
  • Historically, Invested Capital has averaged $195.5 million across 5 years, with a median of $229.9 million in 2023.
  • Biggest YoY gain for Invested Capital was 972.7% in 2022; the steepest drop was 115.1% in 2022.
  • Year by year, Invested Capital stood at -$31.3 million in 2021, then skyrocketed by 972.7% to $272.9 million in 2022, then fell by 15.44% to $230.8 million in 2023, then grew by 11.28% to $256.8 million in 2024, then decreased by 17.98% to $210.6 million in 2025.
  • Business Quant data shows Invested Capital for SPRY at $210.6 million in Q4 2025, $243.9 million in Q3 2025, and $192.3 million in Q2 2025.